Table 1.
Demographic and clinical characteristics of IBD patients in the SECURE-IBD registry based on prescription practice in the setting of COVID-19.
| Characteristica,b | All patients on ≥1 medication | IBD medication stopped | IBD medication not stopped | p-value | |||
|---|---|---|---|---|---|---|---|
| N [mean] | % [SD] | N [mean] | % [SD] | N [mean] | % [SD] | ||
| Total number of patients | 1499 | 518 | 31.8% | 981 | 60.2% | - | |
| Age | 44 | 17.88 | 43 | 16.77 | 44 | 18.43 | 0.276 |
| Female sex | 752 | 48% | 242 | 47% | 485 | 49% | 0.290 |
| Race | |||||||
| White | 1221 | 81% | 420 | 81% | 801 | 82% | 0.787 |
| Black or African American | 96 | 6% | 35 | 7% | 61 | 6% | 0.685 |
| American Indian/Native Alaskan | 2 | 0% | 1 | 0% | 1 | 0% | 0.646 |
| Asian | 87 | 6% | 33 | 6% | 54 | 6% | 0.495 |
| Native Hawaiian/Pacific Islander | 0 | 0% | 0 | 0% | 0 | 0% | - |
| Other | 115 | 8% | 47 | 9% | 68 | 7% | 0.138 |
| Hispanic/Latino | 0.409 | ||||||
| Yes | 262 | 17% | 100 | 19% | 162 | 17% | |
| No | 930 | 62% | 314 | 61% | 616 | 63% | |
| Unknown | 186 | 12% | 66 | 13% | 120 | 12% | |
| Missing | 121 | 8% | 38 | 7% | 83 | 8% | |
| Country | |||||||
| USA | 514 | 34% | 172 | 33% | 342 | 35% | 0.520 |
| Spain | 225 | 15% | 80 | 15% | 145 | 15% | 0.732 |
| France | 90 | 6% | 32 | 6% | 58 | 6% | 0.837 |
| Italy | 74 | 5% | 16 | 3% | 58 | 6% | 0.016 |
| UK | 71 | 5% | 26 | 5% | 45 | 5% | 0.708 |
| Iran | 53 | 4% | 20 | 4% | 33 | 3% | 0.620 |
| Russian | 79 | 5% | 32 | 6% | 47 | 5% | 0.253 |
| Brazil | 50 | 3% | 24 | 5% | 26 | 3% | 0.042 |
| Other | 343 | 23% | 116 | 22% | 227 | 23% | 0.744 |
| Disease type | <0.001 | ||||||
| Crohn’s disease | 821 | 55% | 325 | 63% | 496 | 51% | |
| Ulcerative Colitis | 649 | 43% | 187 | 36% | 462 | 47% | |
| IBD-unspecified | 24 | 2% | 4 | 1% | 20 | 2% | |
| IBD disease activityc | 0.702 | ||||||
| Remission | 854 | 57% | 292 | 56% | 562 | 57% | |
| Mild | 273 | 18% | 92 | 18% | 181 | 18% | |
| Moderate | 240 | 16% | 90 | 17% | 150 | 15% | |
| Severe | 80 | 5% | 24 | 5% | 56 | 6% | |
| Comorbid conditions | |||||||
| Any condition | 555 | 37% | 194 | 37% | 361 | 37% | 0.804 |
| Cardiovascular disease | 109 | 7% | 32 | 6% | 77 | 8% | 0.236 |
| Diabetes | 88 | 6% | 32 | 6% | 56 | 6% | 0.713 |
| Lung disease | 144 | 10% | 42 | 8% | 102 | 10% | 0.153 |
| Hypertension | 194 | 13% | 75 | 14% | 119 | 12% | 0.198 |
| Cancer | 33 | 2% | 10 | 2% | 23 | 2% | 0.603 |
| History of stroke | 19 | 1% | 5 | 1% | 14 | 1% | 0.447 |
| Chronic renal disease | 33 | 2% | 8 | 2% | 25 | 3% | 0.208 |
| Chronic liver disease | 52 | 3% | 17 | 3% | 35 | 4% | 0.774 |
| Other | 214 | 14% | 77 | 15% | 137 | 14% | 0.636 |
| Current smoker | 63 | 4% | 18 | 3% | 45 | 5% | 0.307 |
| BMI | 0.491 | ||||||
| BMI <30 | 925 | 62% | 315 | 61% | 610 | 62% | |
| BMI >=30 | 249 | 17% | 82 | 16% | 167 | 17% | |
| Missing | 325 | 22% | 121 | 23% | 204 | 21% | |
| COVID-19 related emergency room visit | 549 | 37% | 188 | 36% | 361 | 37% | 0.847 |
| COVID-19 related hospitalisation | 422 | 28% | 147 | 28% | 275 | 28% | 0.887 |
Statistically significant associations are in bold.
IBD, inflammatory bowel disease; SD, standard deviation; BMI, body mass index.
aUnless otherwise specified, percentages do not include missing values or ‘unknown’. For all characteristics, unless noted above, less than 4% of data were missing and unknown, respectively, for each category.
bPercentages and n from each subcategory may not add up to the exact number of total reported cases, due to missing values and/or non-mutually exclusive variables.
cBy physician global assessment [PGA] at time of COVID-19 infection.